Aardvark Therapeutics (NASDAQ:AARD) Receives “Buy” Rating from HC Wainwright

HC Wainwright reiterated their buy rating on shares of Aardvark Therapeutics (NASDAQ:AARD) in a research report sent to investors on Monday,Benzinga reports. The firm currently has a $40.00 price target on the stock.

AARD has been the topic of several other research reports. Oppenheimer initiated coverage on Aardvark Therapeutics in a report on Tuesday, December 23rd. They set an “outperform” rating and a $35.00 price objective on the stock. William Blair began coverage on Aardvark Therapeutics in a research note on Friday, December 12th. They issued an “outperform” rating on the stock. Royal Bank Of Canada dropped their price objective on shares of Aardvark Therapeutics from $19.00 to $18.00 and set an “outperform” rating for the company in a research note on Friday, November 14th. Weiss Ratings reiterated a “sell (d-)” rating on shares of Aardvark Therapeutics in a report on Monday, December 29th. Finally, BTIG Research started coverage on shares of Aardvark Therapeutics in a report on Friday, November 7th. They issued a “buy” rating and a $26.00 target price for the company. One research analyst has rated the stock with a Strong Buy rating, eleven have given a Buy rating and one has issued a Sell rating to the company’s stock. According to data from MarketBeat.com, the company currently has a consensus rating of “Moderate Buy” and an average target price of $32.64.

Aardvark Therapeutics Price Performance

Shares of NASDAQ AARD opened at $13.48 on Monday. The company has a 50-day simple moving average of $13.84 and a 200-day simple moving average of $12.17. The company has a market cap of $293.46 million and a PE ratio of -6.36. Aardvark Therapeutics has a 12 month low of $4.88 and a 12 month high of $19.58.

Aardvark Therapeutics (NASDAQ:AARD) last announced its quarterly earnings data on Thursday, November 13th. The company reported ($0.75) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.82) by $0.07.

Insider Transactions at Aardvark Therapeutics

In other Aardvark Therapeutics news, CFO Nelson Sun bought 3,000 shares of the company’s stock in a transaction that occurred on Thursday, December 11th. The stock was purchased at an average price of $14.40 per share, with a total value of $43,200.00. Following the transaction, the chief financial officer owned 108,484 shares in the company, valued at $1,562,169.60. This trade represents a 2.84% increase in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is available at the SEC website. Also, CEO Tien-Li Lee purchased 7,000 shares of the business’s stock in a transaction that occurred on Thursday, December 11th. The stock was acquired at an average price of $14.48 per share, for a total transaction of $101,360.00. Following the acquisition, the chief executive officer directly owned 1,551,613 shares of the company’s stock, valued at $22,467,356.24. This trade represents a 0.45% increase in their position. Additional details regarding this purchase are available in the official SEC disclosure.

Hedge Funds Weigh In On Aardvark Therapeutics

Several hedge funds and other institutional investors have recently made changes to their positions in AARD. Two Sigma Investments LP acquired a new position in shares of Aardvark Therapeutics during the third quarter worth about $845,000. Bridgeway Capital Management LLC purchased a new stake in shares of Aardvark Therapeutics during the 3rd quarter valued at about $292,000. UBS Group AG lifted its position in Aardvark Therapeutics by 5.4% during the 3rd quarter. UBS Group AG now owns 54,728 shares of the company’s stock worth $727,000 after acquiring an additional 2,804 shares in the last quarter. BNP Paribas Financial Markets boosted its holdings in Aardvark Therapeutics by 59.3% in the 3rd quarter. BNP Paribas Financial Markets now owns 56,546 shares of the company’s stock worth $751,000 after acquiring an additional 21,052 shares during the period. Finally, Bank of America Corp DE grew its position in Aardvark Therapeutics by 72.9% in the second quarter. Bank of America Corp DE now owns 7,989 shares of the company’s stock valued at $108,000 after acquiring an additional 3,369 shares in the last quarter.

Aardvark Therapeutics Company Profile

Aardvark Therapeutics, Inc is a clinical-stage biopharmaceutical company based in Cambridge, Massachusetts, specializing in the discovery and development of small-molecule modulators of the retinoic acid receptor–related orphan receptor gamma (RORγ). RORγ plays a central role in T-helper 17 (Th17) cell differentiation and inflammatory processes. By targeting this transcription factor, Aardvark aims to address a range of autoimmune and immune-mediated diseases.

The company’s lead programs consist of selective RORγ inverse agonists designed to suppress pathogenic Th17-driven responses in conditions such as psoriasis, inflammatory bowel disease and other chronic inflammatory disorders.